Decoding the role of neuroinflammation in the pathophysiology of neurodegenerative diseases is a crucial step toward possible therapeutic strategies.

Acknowledgments: We thank the patients and volunteers who participated in this study. A. Blyth, H. McDevitt, and L. Schnorr provided expert technical assistance with PET data acquisition. N. Quinn and C. Mathias, National Hospital for Neurology and Neurosurgery, London, kindly helped with patient identification.

References
1. Wenning GK, Gilman S, Seppi K. Second consensus statement on the diagnosis of multiple system atrophy. Aktuelle Neurologie 2008; 35:670-676.
2. Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011;34:581-590.
3. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuro pathology 2006;26:338-345.
4. Brück D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis 2016;85:262-274.
5. Vieira B, Radford RA, Chung RS, Guillemin GJ, Pountney DL. Microglial activation parallels system degeneration in multiple system atrophy. Neuropathology 2008;28:249-257.
6. Ishizawa K, Komori T, Araí N, Mizutani T, Hirose T. Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology 2008;28:249-257.
7. Ishizawa K, Komori T, Sasaki S, Araí N, Mizutani T, Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 2004;63:43-52.
8. Ginhoux F, Lim S, Hoefell G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci 2013;7:45.
9. Kreutzberg G. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
10. Papadopoulos V, Baraldi M, Guillaume T, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-409.
11. Turkheimer F, Rizzo G, Bloom m, et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans 2015;43:586-592.
12. Gerhard A, Banati RB, Goerres GB, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61:686-689.
13. Spinks TJ, Jones D, Bailey DL, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992;37:1637-1655.
14. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006;21:404-412.
15. Gunn R, Lamontagne A, Hume S, Cunningham V. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6:279-287.
16. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123(Pr 11):2321-2337.
17. Hammers A, Allom R, Koepp M, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003;19:224-247.
18. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 1991;14:9-30.
19. Turkheimer FE, Smith CB, Schmidt K. Estimation of the number of ‘true’ null hypotheses in multivariate analysis of neuroimaging data. Neuroimage 2001;13:920-930.
20. Tai Y, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 2007;130:1759-1766.
21. Stokholm M, Ianzon A, Ostergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. The Lancet Neurology 2017;16(10):789-798.
22. Gerhard A. TSPO imaging in parkinsonian disorders. Clin Transl Imaging 2016;4:183-190.
23. Hamelin L, Lagarde J, Dorothée G, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain 2016;139:1252-1264.
24. Fan Z, Okello A, Brooks D, Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain 2015;138:3685-3698.
25. Janssen B, Vughts D, Windhorst A, Mach R. PET imaging of microglial activation—beyond targeting TSPO. Molecules 2018;23:607.
26. Cuming P, Burgher B, Patkar O, et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab 2017;38:204-224.

Supporting Data
Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

Clinical Heterogeneity of Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Caused by MAPT N279K Mutation in Relation to Tau Positron Emission Tomography Features

Aya Ikeda, MD,1 Hitoshi Shimada, MD, PhD,2 Kenya Nishioka, MD, PhD,1 Masashi Takanashi, MD, PhD,1 Arisa Hayashida, MD,1 Yuanze Li, MD, PhD,1 Hiroyo Yoshino, PhD,3 Manabu Funayama, PhD,1,3 Yuji Ueno, MD, PhD,1 Taku Hatano, MD, PhD,1 Naruhiko Sahara, PhD,2 Tetsuya Suhara, MD, PhD,2 Makoto Higuchi, MD, PhD,2* and Nobutaka Hattori, MD, PhD1,3*

1Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan 2Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan 3Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Japan
ABSTRACT

Background: While mechanistic links between tau abnormalities and neurodegeneration have been proven in frontotemporal dementia and parkinsonism linked to chromosome 17 caused by MAPT mutations, variability of the tau pathogenesis and its relation to clinical progressions in the same MAPT mutation carriers are yet to be clarified.

Objectives: The present study aimed to analyze clinical profiles, tau accumulations, and their correlations in 3 kindreds with frontotemporal dementia and parkinsonism linked to chromosome 17 attributed to the MAPT N279K mutation.

Methods: Four patients with N279K mutant frontotemporal dementia and parkinsonism linked to chromosome 17/MAPT underwent [11C]PBB3-PET to estimate regional tau loads.

Results: Haplotype assays revealed that these kindreds originated from a single founder. Despite homogeneity of the disease-causing MAPT allele, clinical progression was more rapid in 2 kindreds than in the other. The kindred with slow progression showed mild tau depositions, mostly confined to the midbrain and medial temporal areas. In contrast, kindreds with rapid progression showed profoundly increased [11C]PBB3 binding in widespread regions from an early disease stage.

Conclusions: [11C]PBB3-PET can capture four-repeat tau pathologies characteristic of N279K mutant frontotemporal dementia and parkinsonism linked to chromosome 17/MAPT. Our findings indicate that, in addition to the mutated MAPT allele, genetic and/or epigenetic modifiers of tau pathologies lead to heterogeneous clinicopathological features. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: frontotemporal dementia; MAPT; N279K mutation; tau PET

Tau protein fibrillation has been implicated in Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTLD) subtypes and related disorders, which are collectively referred to as tauopathies.1 FTLD tauopathies, including PSP and corticobasal degeneration (CBD), are characterized by the deposition of four-repeat tau isoforms in neurons, astrocytes, and oligodendrocytes.2 Distinct tau isoforms cause ultrastructural and conformational diversity of the pathological filbris, represented by paired helical filaments in AD and straight filaments in PSP and CBD.3

Despite the association between tau conformers, localization of tau lesions, and clinical phenotypes, the symptomatic manifestations and progression of a single tauopathy can vary.4,6 The microtubule-associated protein tau (MAPT) haplotypes may account for the clinicopathological characteristics of PSP7 and frontotemporal dementia (FTD).4,8 Moreover, a number of MAPT mutations cause familial tauopathies, which are termed frontotemporal dementia and parkinsonism linked to chromosome 17 MAPT (FTDP-17/MAPT). However, the symptomatic profiles of patients carrying identical MAPT mutations are also variable.9,12

Evaluation of the correlation between the clinical course and chronological sequence of regional pathological involvement has been enabled by in vivo PET of tau lesions in humans. The radioligands [11C]pyridinyl-butadienyl-benzothiazole 3 ([11C]PBB3), binds to a wide range of tau fibrils, including AD, PSP, and putative CBD tau deposits.13,15 Other tracers, such as [18F]AV-1451, produce a higher contrast for AD-type tau tangles than it does for four-repeat tau inclusions in PSP and CBD,16,17 although [18F]AV-1451 has enabled differentiation between groups of PSP patients and healthy controls.18 The distinct selectivity of the PET ligands could help identify tau isoforms contributing to unique neurodegenerative pathologies in each individual.19

The MAPT N279K mutation was discovered in the white pallidopontonigral degeneration (PPND) kindred20

Relevant conflicts of interest/financial disclosures: H.S., M.H., and T.S. hold a patent on compounds related to the present report (JP 5422782/EP 12 884 742.3), and National Institutes for Quantum and Radiological Science and Technology made a license agreement with APRINOIA Therapeutics Inc. regarding this patent.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 14 June 2018; Revised: 8 December 2018; Accepted: 2 January 2019

Published online 17 February 2019 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27623
and was also found in 6 Japanese kindreds.\textsuperscript{21-23} In the present work, we further identified two novel Japanese families with hereditary tauopathy caused by the N279K mutation, and we investigated the abundance and extent of tau deposits in patients harboring the MAPT N279K mutation derived from three pedigrees, including these two families. Because our previous in vitro assays demonstrated binding of \textsuperscript{[11C]}PBB3 to N279K mutant four-repeat tau aggregates,\textsuperscript{19} \textsuperscript{[11C]}PBB3-PET allowed us to analyze fibrillar tau pathologies in living patients in these families. The haplotypes of all mutant MAPT allele carriers examined here were identical, presumably originating from a single founder. However, there was a profound difference in the progression of functional impairments among these 3 kindreds, in close association with the severity of PET-detectable tau pathologies.

Patients and Methods

Participants

The current study was approved by the local ethics committees of the Juntendo University School of Medicine and National Institute of Radiological Sciences, of which the registration numbers of UMIN are #000009863 and #000017978. All participants or caregivers were fully informed and provided written consent. Verbal ascent was obtained from demented patients and was confirmed by their caregivers. We enrolled 10 patients with FTDP-17 attributed to MAPT N279K mutation, and 6 of these patients were derived from 2 newly identified kindreds (families A and B; Supporting Information Table S1, Supporting Information Case Presentation). Procedures to analyze their MAPT genes are described in the Supporting Information Materials and Methods. Four participants were derived from a pedigree reported on previously (designated family C in the present study and family D in our earlier report\textsuperscript{2}; Supporting Information Table S1, Supporting Information Case Presentation). We also included 13 age- and sex-matched cognitively healthy controls (HCs), who have been already confirmed as having a negative \textsuperscript{[11C]}Pittsburgh Compound-B (\textsuperscript{[11C]}PiB) PET scan in our previous study.\textsuperscript{10}

Tau and Amyloid PET Imaging

PET scans with \textsuperscript{[11C]}PBB3 and \textsuperscript{[11C]}PiB were performed on 4 patients (A-II-1, B-II-2, C-IV-1, and C-IV-2) to estimate regional tau and amyloid-\(\beta\) loads, respectively, as described in the Supporting Information Materials and Methods. Two patients received scans within 1 year of clinical onset of the disease, whereas the other 2 patients underwent scans relatively late. We generated parametric images of the standardized uptake value ratio (SUVR) for \textsuperscript{[11C]}PBB3 and \textsuperscript{[11C]}PiB at 30 to 50 and 50 to 70 minutes, respectively, after radioligand injection, using the cerebellar cortex as a reference region. To estimate local tau and amyloid-\(\beta\) burdens, we performed volume of interest (VOI)-based quantifications of SUVRs for a group analysis, and conducted a voxel-by-voxel jackknife examination of parametric SUVR images to statistically assess distributions of areas with an increased \textsuperscript{[11C]}PBB3 retention in each patient compared to 13 HCs. Detailed analytical procedures are provided in the Supporting Information Materials and Methods.

Results

Clinical and Genetic Profiles

Clinical and genetic characteristics of all 10 patients are summarized in Supporting Information Table S1 and Supporting Information Figure S1, and detailed clinical information of all patients and family members is described in the Supporting Information Case Presentation. Despite the haplotypic homogeneity of the mutant MAPT allele among the patients, Kaplan-Meier analysis depicted significant differences in the survival proportions between combined A and B families and family C (\(P = 0.01\)) by log-rank test; Supporting Information Fig. S1C). Members of family C had a better prognosis than those of families A and B.

PET Imaging

Compared to HCs, all scanned patients had larger \textsuperscript{[11C]}PBB3 SUVRs in characteristic brain regions, including neocortical gray and white matter (Table 1; Fig. 1A). This was distinct from the gray matter–dominant topology of tau depositions in the AD spectrum\textsuperscript{13,14} and corresponded to previous \textsuperscript{[11C]}PBB3 autoradiographical findings.\textsuperscript{19} Subject C-IV-1 had the shortest interval between onset and PET scans and exhibited a remarkable increase of \textsuperscript{[11C]}PBB3 SUVRs in the midbrain, including the SN, hippocampus, and amygdala, suggesting that tau pathologies could arise from these regions (Fig. 1A). Tau deposits appeared to expand from the brainstem and limbic areas to the neocortex and subcortical nuclei with disease progression, given that subject C-IV-2, who underwent PET assays 4 years after onset, presented more widespread and greater increase of \textsuperscript{[11C]}PBB3 binding involving neocortical white matter, globus pallidus, and thalamus than subject C-IV-1 (Table 1).

In line with the notable difference in the rate of progression to death between families A/B and C, a subject from family B (B-II-2), who was scanned 12 months after onset, had even higher levels of \textsuperscript{[11C]}PBB3 retentions in most VOIs than subject C-IV-2, despite the relatively early stage of the clinical course (Fig. 1A). Radioligand binding in subject A-II-1, a member of family A undergoing PET...
examinations 3 years after onset, was comparable with that of subject B-II-2 in the majority of VOIs, although additional increases of \([11C]PBB3\) SUVRs were noted in several areas, including the parahippocampal gyrus and amygdala (Table 1). Therefore, PET-visible tau pathologies in families A and B seemingly plateaued early during clinical progression. None of the patients were amyloid-\(\beta\) positive according to visual and quantitative assessments of \([11C]PiB\)-PET data, which were conducted as in previous studies.\(^{10}\)

In order to highlight areas with increased \([11C]PBB3\) retentions on brain maps, we also conducted voxel-based statistical assessments of SUVR images for this tracer. SPM t-maps depicted enhanced \([11C]PBB3\) radiosignals rather confined to the brainstem and a few other regions, including the hippocampus in family C, which was in sharp contrast with increases of radioligand binding in extensive areas containing neocortical gray and white matter in families A and B (Fig. 1B). This familial difference was observed in subjects with both short and long durations, notwithstanding that areas highlighted in the SPM maps were somewhat increased in a manner dependent on the disease duration.

**Discussion**

We documented three Japanese families with the N279K FTDP-17/\(MAPT\) mutation originating from a founder according to a haplotype analysis. Two of these kindreds (A and B) are newly identified and are characterized by markedly rapid clinical progression, leading to death within 5 years of disease onset. In contrast, the third kindred (family C) showed relatively slow clinical progression.
with an approximate postonset survival period of 10 years.
Hence, the present data illustrated a pronounced interfami-
lial difference in the aggressiveness of the illness, despite
the similarity of their mutant MAPT allele.

Previous studies reported that patients with FTDP-17/MAPT, which could be linked to the same single mutation, demonstrated inter- and intrafamilial heterogeneity in clinicopathological features, including ages at
onset and death, disease duration, clinical symptoms, brain atrophy, and pathological findings. Taking together with the present results, these observations support the view that the MAPT mutation alone may not fully define the clinical and neuropathological outcomes, which could in fact be modulated by other genetic and/or environmental components.

The PET results of the present study provide the first demonstration of heterogeneous neuroimaging phenotypes among patients with FTDP-17/MAPT who possess the same pathogenic mutation and MAPT allele haplotype. In close association with clinical progress, affected cases in families A and B exhibited extensive increases of \([11C]PBB3\) binding in neocortical and subcortical areas from an early period after onset. Enhancement of \([11C]PBB3\) binding, however, was less prominent in patients from family C, who had a longer clinical duration than those from the other two families. These findings indicated that the formation of tau lesions in families A and B occurred rapidly at the perionset stage and then almost plateaued at an early postonset stage. This was then followed by a prompt evolution of functional deteriorations, resulting in a short life span of the affected members after onset. This may also suggest the significance of tau PET as a predictor of the following neurodegenerative processes, resembling findings in patients with AD, who show a tight correlation between baseline retention of a tau PET probe and subsequent longitudinal atrophy of the cortex.

The symptomatic profiles of the current N279K mutant cohort were all PSP like, consistent with previous studies. However, two patients from family A initially presented personality changes (Supporting Information Table S1), raising the possibility that there is a variable chronology of neuropsychiatric phenotypes within pedigrees of a common origin. Similar diversities were also noted in members of PPND and Italian families with the N279K mutation and were conceived to stem from the H1/H2 haplotypes of MAPT. Given that the Japanese population does not possess the H2 haplotype, the personality-related presentation of initial symptoms observed in family A, but not in the other two families, could be attributed to additional genotypic variations located on the nonmutant MAPT allele and/or non-MAPT elements.

Parkinsonian symptoms in affected individuals from family C from an early clinical stage are typical of the N279K mutation and could be induced by involvement of the extrapyramidal tract in tau pathologies. Indeed, a profound increase of \([11C]PBB3\) binding in subject C-IV-1 with a short postonset duration was particularly evident in the SN (Table 1), which might be an initiation site of tau fibrillogenesis at a preclinical stage. This may be in line with our previous PET findings, where the nigrostriatal dopaminergic system was disrupted in presymptomatic carriers of the N279K mutation derived from the PPND pedigree. Meanwhile, the origin of tau depositions in members of family A with initial manifestations dominated by psychiatric signs has yet to be clarified. The tau PET data of subject C-IV-1 (in the current study) also suggest that tau pathologies in the amygdala and hippocampal formation emerge early during the clinical course. This might elicit local neuronal death and atrophic changes, as illustrated by an MRI analysis of the above-mentioned N279K mutant carriers at a prodromal disease stage.

Similar to the AD spectrum, the extent of tau pathologies may reflect the disease progression in N279K mutant cases. However, the tau pathogenesis, even in family C, appeared to be rapidly progressive relative to AD. Moreover, regions and voxels with increased \([11C]PBB3\) binding in neocortical white matter of mutation carriers from all three families expanded over time, which differed from the gray matter–predominant distribution of tau fibrils in AD. Deposition of tau assemblies in white matter may be a neuropathological characteristic of familial and sporadic FTLDs with an excess of insoluble four-repeat tau isoforms.

A few technical issues need to be considered in the interpretation of the current PET data. In vivo off-target binding and nonspecific retention of \([11C]PBB3\) remain undetermined. Our recent in vitro binding assays using human brain homogenates have indicated that \([11C]PBB3\) does not cross-react with monoamine oxidases A and B, which is in clear distinction from properties of other tau radioligands, including \([18F]AV-1451\) and \([18F]THK5351\). This observation, however, does not fully ensure the selectivity of \([11C]PBB3\) for tau fibrils in PET imaging of living patients with tauopathies. Another methodological issue is that tau deposits might exist in a portion of the reference VOI defined in cerebellar gray matter. This might occur in a case with severe and widespread tau accumulations as exemplified by subject A-II-1 (indicated in a sagittal map of Fig. 1B), potentially leading to underestimation of radioligand SUVRs in target areas and voxels.

In conclusion, the current study delineated the neuropathological basis of the clinical phenotypes in living patients with FTDP-17/MAPT, underscoring the contribution of factors beyond the disease-causative MAPT haplotypes and mutations to prompt the spread of tau and clinical progress. Although these modifiers are still unidentified, there could be common accelerators or decelerators of tau pathologies across a wide range of tauopathies. Moreover, our imaging assay has supported the significance of the baseline extent of tau lesions at an early clinical stage as a predictor of rapid and slow subsequent disease progressions. In the event that future clinical assays demonstrate that this can be translated to other four-
repeat tauopathies, tau PET would help to stratify an observational or interventional cohort of participants, based on an expected rate of clinical and pathological advancements.

References

1. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013;12:609–622.

2. Murray ME, Koura N, Lin WL, Jack CR, Jr., Dickson DW, Vemuri P. Clinico pathological assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014;6:1.

3. Quadros A, Ophelia I, Ghania A. Role of tau in Alzheimer’s dementia and other neurodegenerative diseases. J Appl Biomed 2007;5:1–12.

4. Morris HR, Gibb G, Katzenschlager R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002;125(Pt 5):969–975.

5. Wakabayashi K, Takahashi H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuro pathology 2004;24:79–86.

6. Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther 2013;5:11.

7. Conrad C, Andreadis A, Torenjowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277–281.

8. Laws SM, Pernezky R, Drzezga A, et al. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. Am J Psychiatry 2007;164:1577–1584.

9. Janssen JC, Warrington EK, Morris HR, et al. Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology 2002;58:1161–1168.

10. Boeve BF, Tremont-Lukats IW, Wachawik AJ, et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain 2005;128(Pt 4):752–772.

11. Doran M, du Plessis DG, Ghaldiali EJ, Mann DM, Pickering-Brown S, Larner AJ. Familial early-onset dementia with tau intron 10 +16 mutation with clinical features similar to those of Alzheimer disease. Arch Neurol 2007;64:1335–1339.

12. Tacik P, Sanchez-Contreras M, DeTure M, et al. Clinico-pathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.301H mutation, including a patient with globular glial tauopathy. Neuroophthalmol Appl Neurobiol 2017;43:200–214.

13. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79:1094–1108.

14. Shimada H, Kitamura S, Shinotoh H, et al. Association between Abeta and tau accumulations and their influence on clinical features in aging and Alzheimer’s disease spectrum brains: a [11C]PBB3-PET study. Alzheimers Dement (Amst) 2017;6:61–70.

15. Perez-Soriano A, Arena JE, Dinelle K, et al. PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord 2017;32:1016–1024.

16. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787-800.

17. Marquie M, Normandin MD, Zeltzer AC, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer’s tauopathies. Ann Neurol 2017;81:117–128.

18. Schonhaut DR, McMillan CT, Spina S, et al. 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol 2017;82:622–634.

19. Ono M, Sahara N, Kumata K, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 2017;140:764–780.

20. Yasuda M, Kawamata T, Komure O, et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 1999;53:864–868.

21. Arima K, Kowalska A, Hasegawa M, et al. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000;54:1787–1795.

22. Tsuibo Y, Baker M, Hutton ML, et al. Clinical and genetic studies of families with the tau N279K mutation. Neurology 2002;59:1791–1793.

23. Ogaki K, Li Y, Takamishi M, et al. Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. Parkinsonism Relat Disord 2013;19:15–20.

24. Lin HC, Lin CH, Chen PL, Cheng SJ, Chen PH. Intrafamilial phenotypic heterogeneity in a Taiwanese family with a MAPT p.R5H mutation: a case report and literature review. BMC Neuro 2017;17:186.

25. La Joie R, Visani A, Bourakova V, et al. AV1451-PET cortical uptake and regional distribution predict longitudinal atrophy in Alzheimer’s disease. Alzheimer Dem 2017;13:P769.

26. Tsuibo Y, Uitti RJ, Delise MB, et al. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. Arch Neurol 2002;59:943–950.

27. Soliven P, Rossi G, Monza D, et al. A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol 2003;60:1454–1456.

28. Woodruff BK, Baba Y, Hutton ML, et al. Haploype-phenotype correlations in kindreds with the N279K mutation in the tau gene. Arch Neurol 2004;61:1327; author reply, 1327.

29. Miyoshi M, Shinotoh H, Wszolek ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord 2010;16:404–408.

30. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;81:239–259.

31. Wszolek ZK, Pfieffer RF, Bhattacharyya, et al. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-pontine degeneration. Ann Neurol 1992;32:312–320.

32. Delise MB, Murrell JR, Richardson R, et al. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol 1999;98:62–77.

33. Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 2002;160:2045–2053.

34. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007;130:1566–1576.

35. Ni R, Ji B, Ono M, et al. Comparative in vitro and in vivo quantifications of pathologic tau deposits and their association with neurodegeneration in tauopathy mouse models. J Nucl Med 2018;59:960–966.

36. Vermeiren C, Motte P, Vist D, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monomeric oxides. Mov Disord 2018;33:273–281.

37. Ng KP, Pascoal TA, Mathothrarachi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther 2017;9:225.

 Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.